Novartis, Novo Nordisk CV drug failures may chill pharma R&D investment

Back-to-back Phase 3 failures of cardiovascular drugs from Novartis and Novo Nordisk have raised concerns about the viability of the therapeutic area, potentially dampening industry-wide investment in similar programs. The failures are confirmed by company announcements, but the broader chilling effect on the field is an emerging inference. This matters because it could redirect R&D capital away from cardiovascular targets, affecting future drug development pipelines.